Richard Lam, MD
Hospice and Palliative Medicine · Pasadena, CANPI 1831519115
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $229 and has fallen 55.0% since, to $103 in 2025.
Across 35 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blue Earth Diagnostics$169
- Dendreon Pharmaceuticals LLC$133
- Sanofi$125
- Johnson & Johnson$113
- Lilly USA, LLC$83
- Mannkind Corporation$70
- plus $110 from 4 others
What the payments were for
- Food & beverage$803100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blue Earth Diagnostics | 7 | $169 |
| Dendreon Pharmaceuticals LLC | 5 | $133 |
| Sanofi | 5 | $125 |
| Johnson & Johnson | 6 | $113 |
| Lilly USA, LLC | 4 | $83 |
| Mannkind Corporation | 3 | $70 |
| Bayer | 2 | $48 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Tolmar, Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
How this compares
$803 in reported general payments places this provider in the 85th percentile of 195 hospice and palliative medicine providers in California.
See all hospice and palliative medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrilosecOmeprazole Magnesium | 14 | $18,344 |
| XcopriCenobamate | 12 | $12,803 |
| Levothyroxine Sodium | 12 | $165 |
| FenofibrateFenofibrate Nanocrystallized | 11 | $144 |
| Pantoprazole Sodium | 11 | $68 |
| Phenobarbital | 12 | $51 |
Paid to pharmacies, not to this prescriber.
Other hospice and palliative medicine in Pasadena
- Norr SantzPasadena$2K
- Christopher BuiPasadena$895
- Rafik MughnetsyanPasadena$581
- Chandra JainPasadena$208
- Sharon YeeArcadia$44K
- Neil SoniFountain Valley$28K
- Marietta Abalos-GalitoSan Jose$21K
- Humayon KhanSanta Ana$7K
- Sorin BugaDuarte$5K
- Glenn CarrFresno$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.